.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a growing global epidemic. Experts now categorize MASLD as a hepatic manifestation of systemic metabolic disorders. This condition involves insulin resistance, obesity, and chronic inflammation. Understanding the epigenetic mechanisms in MASLD is essential for identifying patients at high risk of progression. These mechanisms allow environmental factors to influence gene activity without changing the primary DNA sequence.
Recent research highlights several key drivers of liver dysfunction. DNA methylation stands out as a primary regulatory process. It involves the addition of methyl groups to CpG sites, which often silences protective genes. Histone modifications also play a significant role by altering chromatin accessibility. Consequently, these changes can trigger lipid accumulation and promote fibrogenesis in the liver. Furthermore, non-coding RNAs regulate post-transcriptional gene expression. In addition, N6-methyladenosine (m6A) modifications influence the stability of hepatic RNA transcripts. Each of these components contributes to the transition from simple steatosis to severe steatohepatitis.
MASLD correlates strongly with an increased risk of cardiovascular disease. This risk persists regardless of traditional factors like diabetes or hypertension. Interestingly, many epigenetic changes remain reversible through lifestyle or pharmacological interventions. This characteristic makes them ideal targets for developing new therapeutic strategies. Moreover, clinicians can use these markers for better risk stratification. By monitoring specific biomarkers, physicians may soon offer personalized treatment plans for fibrosis. Therefore, staying informed about these biological advances is vital for modern hepatology practice.
The main drivers include DNA methylation, histone modifications, and non-coding RNA regulation. These processes allow environmental factors to alter gene expression without changing the DNA sequence.
MASLD increases the risk of cardiovascular disease independently of traditional risk factors like obesity or hypertension. It is often viewed as the hepatic manifestation of a systemic metabolic syndrome.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Zhelezniakova N et al. The Influence of Epigenetic Mechanisms on the Development of Metabolic Dysfunction Associated Steatotic Liver Disease: A Review. J Gastrointestin Liver Dis. 2026 Mar 27. doi: 10.15403/jgld-6581. PMID: 41894713.
Zheng Q et al. Epigenetic and epitranscriptomic regulations of metabolic dysfunction-associated steatotic liver disease. Metabolism and Target Organ Damage. 2024;4:43. doi:10.20517/mtod.2024.75.
Li X et al. Clinical and pathological characteristics of metabolic dysfunction-associated steatotic liver disease and the key role of epigenetic regulation: implications for molecular mechanism and treatment. PMC. 2025 Mar 17.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Explore the role of epigenetic mechanisms in MASLD, focusing on DNA methylation and histone modifications as drivers of disease progression and therapy....
5 months ago
A new case study illuminates how functional connectivity changes drive recovery from pure alexia following posterior cerebral artery infarction. Functional reorganization supports reading recovery despite permanent structural tract disconnection, highlighting key implications for stroke rehabilitation.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
